Use of magnesium vanadate for the treatment of insulin resistance syndrome

摘要

The use of the compound magnesium vanadate in the manufacture of a pharmaceutical composition for treating human or animal patients suffering from insulin resistance syndromes, particularly diabetes mellitus. Daily dosage ranges are preferably from about 2 to about 60 mg of magnesium vanadate per kg of patient body weight. The pharmaceutical compositions include at least one pharmaceutically acceptable inert ingredient, and may be oral, parenteral, transdermal or transmucosal dosage forms containing from about 50 to about 1000 mg of magnesium vanadate per unit.